Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097825 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
NCT00097825 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 288 participants.
The verdict
NCT00097825, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
Study Summary
The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.
Interventions
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097825
The ClinicalTrials.gov registry entry for NCT00097825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT00097825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097825 about?
NCT00097825 is a clinical study titled "Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men". The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.
What is the current status of trial NCT00097825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2004-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00097825?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00097825?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.